Generalizability of HFrEF trials 35 Supplementary table 1 (continued). Characteristics, inclusion and exclusion criteria of trials Study name BEAUTIFUL CONFIRM-HF FAIR-HF PANTHEON SHIFT LVEF equal to 39% or lower on a recently performed measurement (in the previous 4 weeks) from a two-dimensional echocardiography and left ventricular dilatation on an echocardiographically measured short-axis internal dimension at end diastole greater than 56 mm (exam performed in the previous 4 weeks).Documented sinus rhythm and HR of 60 beats per minute or more on a recent (within 24 hours) resting standard 12-lead ECG LEVF ≤45% (value within 3 months of planned date of randomization). LVEF ≤ 40% for patients in NYHA II and ≤ 45% in NYHA III as assessed according to local methodology by 2-D echocardiography, radionuclide ventriculography, cardiac magnetic resonance imaging, or X-ray contrast ventriculography within 6 months prior to start of treatment. For patients treated with beta-blockers or with cardiac resynchronisation, LVEF assessment for eligibility must be performed at least 12 weeks after stable betablocker therapy or device implantation. LVEF ≤ 35%assessed by any imaging modality within 6 months prior to run in: if several values are available the last assessment of LVEF should be ≤ 35%. LVEF ≤ 35% as measured and documented within the previous 3 months (in a stable condition) by echocardiography, radionuclide ventriculography, magnetic resonance imaging, cardiac angiography or computed tomography angiography.Documente d sinus rhythm and HR ≥ 70 bpm on a recent (within 24 hours) resting standard 12-lead ECG 2.1
RkJQdWJsaXNoZXIy MjY0ODMw